Back Hepatitis C

Hepatitis C

CROI 2015: Hepatitis C -- Mission Accomplished? [VIDEO]

New interferon-free treatment for hepatitis C virus (HCV) has brought about a revolution in treatment, but challenges still remain -- among them too few people with HCV being diagnosed and the high cost of the new drugs -- before the mission can be declared a success. A panel of hepatitis C experts discuss research presented at the recent 2015 Conference on Retroviruses and Opportunistic Infections(CROI) in Seattle with HIVandHepatitis.com editor Liz Highleyman in this IFARA video.

alt

CROI 2015: Liver Disease Progression Is Common Among Baby Boomers with Hepatitis C

The burden of hepatitis C virus (HCV) infection is high in the U.S., with nearly half of HCV-infected individuals born between 1945 and 1965 having severe fibrosis or cirrhosis and therefore being at high priority for treatment, according to a report presented at the 2015 Conference on Retroviruses and Opportunistic Infections (CROI) last week in Seattle.

alt

Clinicians Report 2 Acute HCV Infections in Kaiser PrEP Program

Two HIV negative men gay receiving HIV pre-exposure prophylaxis (PrEP) through Kaiser Permanente in San Francisco were newly infected with hepatitis C virus (HCV), with sex being their only apparent risk factor, Kaiser clinicians reported in the February 18 issue of Clinical Infectious Diseases.

alt

New Hepatitis C Treatments Highly Effective for HIV/HCV Coinfected People

A pair of interferon-free combinations -- AbbVie's 3-drug Viekira Pak regimen and Gilead Science's sofosbuvir/ledipasvir (Harvoni) -- demonstrated good safety and cured more than 90% of genotype 1 HIV/HCV coinfected people, according to studies published in the February 23 advance edition of the Journal of the American Medical Association.

alt

Achillion's ACH-3102 + Sofosbuvir for 6 Weeks Shows 100% Cure Rate

Achillion's next-generation HCV NS5A inhibitor ACH-3102 plus Gilead Science's HCV polymerase inhibitor sofosbuvir (Sovaldi) taken for 6 weeks led to sustained virological response in all previously untreated genotype 1 hepatitis C patients in a small Phase 2 trial, according to a recent company announcement. Achillion now plans to test this same combination taken for just 4 weeks.

alt

CROI 2015: Hepatitis C -- A Light at the End of the Tunnel [VIDEO]

Charles Rice from the Rockefeller University traced the development of scientific knowledge about hepatitis C virus and the evolution of its treatment in a plenary lecture at the 2015 Conference on Retroviruses and Opportunistic Infections (CROI) taking place this week in Seattle.

alt

Studies Find Risk-based Testing Misses Many People with Hepatitis C

Testing for hepatitis C virus (HCV) in primary care settings according to risk factors may fail to identify 80% of people positive for HCV antibodies, according to a report in the January 16 edition of Clinical Infectious Diseases. A related study found that a substantial number of Baby Boomers seen in an Alabama emergency department had undiagnosed chronic HCV infection.

alt

AbbVie Dual Regimen Highly Effective Against HCV Genotype 1b

A 2-drug combination consisting of AbbVie's ritonavir-boosted HCV protease inhibitor parataprevir and NS5A inhibitor ombitasvir -- part of the Viekira Pak regimen -- demonstrated a 95% cure rate for people with hepatitis C virus genotype 1b, the most common type in Japan, according to a recent company announcement.

alt

Liver Cirrhosis Is More Common in U.S. than Previously Believed

New estimates indicate that more than 600,000 people in the U.S. have liver cirrhosis -- about 200,000 more than previously thought -- according to a study published online in the Journal of Clinical Gastroenterology. Cirrhosis was associated with hepatitis C virus (HCV) infection, heavy alcohol use, and diabetes.

alt